Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Paclitaxel + Bevacizumab in HR+/HER2- Advanced Breast Cancer
NCT04732598Phase 3Completed
- Sponsor
- Japanese Foundation for Cancer Research
- Start
- Jan 2021
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in breast cancer, sponsored by Japanese Foundation for Cancer Research. Started Jan 2021; status: completed.
02
Drugs
atezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04732598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04732598.